A rapid rise in circulating pancreastatin in response to somatostatin analogue therapy is associated with poor survival in patients with neuroendocrine tumours | Zendy

Randal L. Stronge | Zendy; Graham B. Turner | Zendy; Brian T. Johnston | Zendy; David R. McCance | Zendy; Ann McGinty | Zendy; CC Patterson | Zendy; J. Ardill | Zendy

Open Access

A rapid rise in circulating pancreastatin in response to somatostatin analogue therapy is associated with poor survival in patients with neuroendocrine tumours

Author(s) -

Randal L. Stronge,

Graham B. Turner,

Brian T. Johnston,

David R. McCance,

Ann McGinty,

CC Patterson,

J. Ardill

Publication year - 2008

Publication title -

annals of clinical biochemistry international journal of laboratory medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.6

H-Index - 80

eISSN - 1758-1001

pISSN - 0004-5632

DOI - 10.1258/acb.2008.008033

Subject(s) - medicine , neuroendocrine tumors , somatostatin , univariate analysis , oncology , multivariate analysis , univariate , octreotide , radionuclide therapy , hazard ratio , proportional hazards model , multivariate statistics , confidence interval , statistics , mathematics

To assess the value of pancreastatin as a predictive factor for identifying patients with neuroendocrine tumours (NETs) who respond poorly to somatostatin analogues.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research